Search

Your search keyword '"Lemnios, Ashley A."' showing total 5 results
Start Over Author "Lemnios, Ashley A."
5 results on '"Lemnios, Ashley A."'

1. Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice

Author

Dalvie, Neil C., Rodriguez-Aponte, Sergio A., Hartwell, Brittany L., Tostanoski, Lisa H., Biedermann, Andrew M., Crowell, Laura E., Kaur, Kawaljit, Kumru, Ozan S., Carter, Lauren, Yu, Jingyou, Chang, Aiquan, McMahan, Katherine, Courant, Thomas, Lebas, Celia, Lemnios, Ashley A., Rodrigues, Kristen A., Silva, Murillo, Johnston, Ryan S., Naranjo, Christopher A., Tracey, Mary Kate, Brady, Joseph R., Whittaker, Charles A., Yun, Dongsoo, Brunette, Natalie, Wang, Jing Yang, Walkey, Carl, Fiala, Brooke, Kar, Swagata, Porto, Maciel, Lok, Megan, Andersen, Hanne, Lewis, Mark G., Love, Kerry R., Camp, Danielle L., Silverman, Judith Maxwell, Kleanthous, Harry, Joshi, Sangeeta B., Volkin, David B., Dubois, Patrice M., Collin, Nicolas, King, Neil P., Barouch, Dan H., Irvine, Darrell J., and Love, J. Christopher

Published
2021

2. Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity

Author

Massachusetts Institute of Technology. Department of Biological Engineering, Hartwell, Brittany L, Melo, Mariane B, Xiao, Peng, Lemnios, Ashley A, Li, Na, Chang, Jason YH, Yu, Jingyou, Gebre, Makda S, Chang, Aiquan, Maiorino, Laura, Carter, Crystal, Moyer, Tyson J, Dalvie, Neil C, Rodriguez-Aponte, Sergio A, Rodrigues, Kristen A, Silva, Murillo, Suh, Heikyung, Adams, Josetta, Fontenot, Jane, Love, J Christopher, Barouch, Dan H, Villinger, Francois, Ruprecht, Ruth M, Irvine, Darrell J, Massachusetts Institute of Technology. Department of Biological Engineering, Hartwell, Brittany L, Melo, Mariane B, Xiao, Peng, Lemnios, Ashley A, Li, Na, Chang, Jason YH, Yu, Jingyou, Gebre, Makda S, Chang, Aiquan, Maiorino, Laura, Carter, Crystal, Moyer, Tyson J, Dalvie, Neil C, Rodriguez-Aponte, Sergio A, Rodrigues, Kristen A, Silva, Murillo, Suh, Heikyung, Adams, Josetta, Fontenot, Jane, Love, J Christopher, Barouch, Dan H, Villinger, Francois, Ruprecht, Ruth M, and Irvine, Darrell J

Abstract

To combat the HIV epidemic and emerging threats such as SARS-CoV-2, immunization strategies are needed that elicit protection at mucosal portals of pathogen entry. Immunization directly through airway surfaces is effective in driving mucosal immunity, but poor vaccine uptake across the mucus and epithelial lining is a limitation. The major blood protein albumin is constitutively transcytosed bidirectionally across the airway epithelium through interactions with neonatal Fc receptors (FcRn). Exploiting this biology, here, we demonstrate a strategy of “albumin hitchhiking” to promote mucosal immunity using an intranasal vaccine consisting of protein immunogens modified with an amphiphilic albumin-binding polymer-lipid tail, forming amph-proteins. Amph-proteins persisted in the nasal mucosa of mice and nonhuman primates and exhibited increased uptake into the tissue in an FcRn-dependent manner, leading to enhanced germinal center responses in nasal-associated lymphoid tissue. Intranasal immunization with amph-conjugated HIV Env gp120 or SARS-CoV-2 receptor binding domain (RBD) proteins elicited 100- to 1000-fold higher antigen-specific IgG and IgA titers in the serum, upper and lower respiratory mucosa, and distal genitourinary mucosae of mice compared to unmodified protein. Amph-RBD immunization induced high titers of SARS-CoV-2–neutralizing antibodies in serum, nasal washes, and bronchoalveolar lavage. Furthermore, intranasal amph-protein immunization in rhesus macaques elicited 10-fold higher antigen-specific IgG and IgA responses in the serum and nasal mucosa compared to unmodified protein, supporting the translational potential of this approach. These results suggest that using amph-protein vaccines to deliver antigen across mucosal epithelia is a promising strategy to promote mucosal immunity against HIV, SARS-CoV-2, and other infectious diseases.

Published
2023

3. Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity

Author

Hartwell, Brittany L., primary, Melo, Mariane B., additional, Xiao, Peng, additional, Lemnios, Ashley A., additional, Li, Na, additional, Chang, Jason Y.H., additional, Yu, Jingyou, additional, Gebre, Makda S., additional, Chang, Aiquan, additional, Maiorino, Laura, additional, Carter, Crystal, additional, Moyer, Tyson J., additional, Dalvie, Neil C., additional, Rodriguez-Aponte, Sergio A., additional, Rodrigues, Kristen A., additional, Silva, Murillo, additional, Suh, Heikyung, additional, Adams, Josetta, additional, Fontenot, Jane, additional, Love, J. Christopher, additional, Barouch, Dan H., additional, Villinger, Francois, additional, Ruprecht, Ruth M., additional, and Irvine, Darrell J., additional

Published
2022
Full Text
View/download PDF

4. Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice

Author

Massachusetts Institute of Technology. Department of Chemical Engineering, Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology. Department of Biological Engineering, Harvard University--MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology. Institute for Medical Engineering & Science, Dalvie, Neil C., Rodriguez-Aponte, Sergio A., Hartwell, Brittany L., Tostanoski, Lisa H., Biedermann, Andrew M., Crowell, Laura E, Kaur, Kawaljit, Kumru, Ozan S., Carter, Lauren, Yu, Jingyou, Chang, Aiquan, McMahan, Katherine, Courant, Thomas, Lebas, Celia, Lemnios, Ashley A., Rodrigues, Kristen A., Silva, Murillo, Johnston, Ryan S., Naranjo, Christopher, Tracey, Mary Kate, Brady, Joseph R., Whittaker, Charles A., Yun, Dongsoo, Brunette, Natalie, Wang, Jing Yang, Walkey, Carl, Fiala, Brooke, Kar, Swagata, Porto, Maciel, Lok, Megan, Andersen, Hanne, Lewis, Mark G., Love, Kerry R., Camp, Danielle L., Silverman, Judith Maxwell, Kleanthous, Harry, Joshi, Sangeeta B., Volkin, David B., Dubois, Patrice M., Collin, Nicolas, King, Neil P., Barouch, Dan H., Irvine, Darrell J, Love, Christopher J., Massachusetts Institute of Technology. Department of Chemical Engineering, Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology. Department of Biological Engineering, Harvard University--MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology. Institute for Medical Engineering & Science, Dalvie, Neil C., Rodriguez-Aponte, Sergio A., Hartwell, Brittany L., Tostanoski, Lisa H., Biedermann, Andrew M., Crowell, Laura E, Kaur, Kawaljit, Kumru, Ozan S., Carter, Lauren, Yu, Jingyou, Chang, Aiquan, McMahan, Katherine, Courant, Thomas, Lebas, Celia, Lemnios, Ashley A., Rodrigues, Kristen A., Silva, Murillo, Johnston, Ryan S., Naranjo, Christopher, Tracey, Mary Kate, Brady, Joseph R., Whittaker, Charles A., Yun, Dongsoo, Brunette, Natalie, Wang, Jing Yang, Walkey, Carl, Fiala, Brooke, Kar, Swagata, Porto, Maciel, Lok, Megan, Andersen, Hanne, Lewis, Mark G., Love, Kerry R., Camp, Danielle L., Silverman, Judith Maxwell, Kleanthous, Harry, Joshi, Sangeeta B., Volkin, David B., Dubois, Patrice M., Collin, Nicolas, King, Neil P., Barouch, Dan H., Irvine, Darrell J, and Love, Christopher J.

Abstract

Global containment of COVID-19 still requires accessible and affordable vaccines for low- and middle-income countries (LMICs). Recently approved vaccines provide needed interventions, albeit at prices that may limit their global access. Subunit vaccines based on recombinant proteins are suited for large-volume microbial manufacturing to yield billions of doses annually, minimizing their manufacturing cost. These types of vaccines are well-established, proven interventions with multiple safe and efficacious commercial examples. Many vaccine candidates of this type for SARS-CoV-2 rely on sequences containing the receptor-binding domain (RBD), which mediates viral entry to cells via ACE2. Here we report an engineered sequence variant of RBD that exhibits high-yield manufacturability, high-affinity binding to ACE2, and enhanced immunogenicity after a single dose in mice compared to the Wuhan-Hu-1 variant used in current vaccines. Antibodies raised against the engineered protein exhibited heterotypic binding to the RBD from two recently reported SARS-CoV-2 variants of concern (501Y.V1/V2). Presentation of the engineered RBD on a designed virus-like particle (VLP) also reduced weight loss in hamsters upon viral challenge.

Published
2021

5. Engineered SARS-CoV-2 receptor binding domain improves immunogenicity in mice and elicits protective immunity in hamsters

Author

Dalvie, Neil C., primary, Rodriguez-Aponte, Sergio A., additional, Hartwell, Brittany L., additional, Tostanoski, Lisa H., additional, Biedermann, Andrew M., additional, Crowell, Laura E., additional, Kaur, Kawaljit, additional, Kumru, Ozan, additional, Carter, Lauren, additional, Yu, Jingyou, additional, Chang, Aiquan, additional, McMahan, Katherine, additional, Courant, Thomas, additional, Lebas, Celia, additional, Lemnios, Ashley A., additional, Rodrigues, Kristen A., additional, Silva, Murillo, additional, Johnston, Ryan S., additional, Naranjo, Christopher A., additional, Tracey, Mary Kate, additional, Brady, Joseph R., additional, Whittaker, Charles A., additional, Yun, Dongsoo, additional, Kar, Swagata, additional, Porto, Maciel, additional, Lok, Megan, additional, Andersen, Hanne, additional, Lewis, Mark G., additional, Love, Kerry R., additional, Camp, Danielle L., additional, Silverman, Judith Maxwell, additional, Kleanthous, Harry, additional, Joshi, Sangeeta B., additional, Volkin, David B., additional, Dubois, Patrice M., additional, Collin, Nicolas, additional, King, Neil P., additional, Barouch, Dan H., additional, Irvine, Darrell J., additional, and Love, J. Christopher, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results